Clinical trial confirms breakthrough treatment for COVID-19: Patients with a self-administered nasal spray found to have reduced SARS-CoV-2 viral load by more than 95% in infected participants within 24 hours
Posted on
ADVERTISEMENT
Patients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours
Trial concluded that treatment accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus a placebo
Randomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variant
No adverse events were recorded in the group
Clinical trial confirms breakthrough treatment for COVID-19
Randomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variant.
ADVERTISEMENT
Patients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours
Trial concluded that treatment accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus a placebo
Randomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variant
No adverse events were recorded in the group
Submission for Emergency Use in the UK and Canada for the treatment and prevention of COVID-19 is planned immediately